Doc­tors with­out Bor­ders asks J&J not to en­force sec­ondary patents for TB drug af­ter gener­ic deal with non­prof­it

Doc­tors with­out Bor­ders crit­i­cized a deal be­tween John­son & John­son and the Stop TB Part­ner­ship that al­lows the Swiss non­prof­it to man­u­fac­ture and sup­ply gener­ic forms of J&J’s tu­ber­cu­lo­sis drug, Sir­turo.

The patent for Sir­turo, or be­daquiline, ex­pired Tues­day in mul­ti­ple coun­tries, ac­cord­ing to Médecins Sans Fron­tières (MSF), the med­ical ad­vo­ca­cy group al­so known as Doc­tors With­out Bor­ders.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER